Why Gilead Sciences' Successful COVID-19 Results Fell Flat
A retrospective analysis said the still-experimental antiviral infusion significantly reduces COVID-19 patients' risk of death.
A retrospective analysis said the still-experimental antiviral infusion significantly reduces COVID-19 patients' risk of death.